Holocene Advisors LP Invests $46.70 Million in Thermo Fisher Scientific Inc. $TMO

Holocene Advisors LP purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter, HoldingsChannel reports. The fund purchased 96,292 shares of the medical research company’s stock, valued at approximately $46,704,000.

Other institutional investors also recently bought and sold shares of the company. Lombard Odier Asset Management Switzerland SA lifted its holdings in shares of Thermo Fisher Scientific by 8.4% in the second quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock valued at $5,875,000 after purchasing an additional 1,128 shares in the last quarter. Cornerstone Investment Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $41,393,000. Weaver Capital Management LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $506,000. VELA Investment Management LLC increased its position in Thermo Fisher Scientific by 65.5% during the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company’s stock worth $4,513,000 after buying an additional 3,683 shares in the last quarter. Finally, NEOS Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 28.6% in the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock worth $24,913,000 after acquiring an additional 11,415 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on TMO. Robert W. Baird set a $653.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 30th. Stifel Nicolaus raised their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Wells Fargo & Company set a $683.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. TD Cowen decreased their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $633.68.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $471.12 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The firm has a market capitalization of $175.01 billion, a price-to-earnings ratio of 26.56, a price-to-earnings-growth ratio of 2.68 and a beta of 0.96. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a 50 day moving average price of $555.03 and a 200 day moving average price of $548.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company earned $6.10 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is currently 10.60%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.